HLA-A Antibody

Definition and Biological Role

HLA-A antibodies are produced against HLA-A molecules, which are MHC class I proteins expressed on all nucleated cells. These antigens present intracellular peptides to cytotoxic T-cells (CD8⁺), enabling immune surveillance . Antibodies against HLA-A arise primarily through sensitization events, such as blood transfusions, pregnancies, or prior transplants .

Key features:

• Structure: Target the α-chain of HLA-A (heavy chain) or β₂-microglobulin .

• Function: Can trigger complement activation, antibody-dependent cellular cytotoxicity (ADCC), and graft rejection .

Assays for HLA-A Antibody Detection

• The Luminex® bead assay detects antibodies with mean fluorescence intensity (MFI) >1,000, enabling precise identification of HLA-A specificities .

• In older transplant candidates, anti-HLA-A antibodies are detected in 24.5% of patients, higher than HLA-C (16.5%) or HLA-DP (8.4%) .

Transplant Rejection

• Mechanism: HLA-A antibodies bind donor endothelial cells, activating complement (C1q) and recruiting macrophages/NK cells .

• Impact: Associated with antibody-mediated rejection (AMR) in 64% of sensitized kidney transplant recipients .

Disease Associations

• HLA-A*11:01-specific antibodies (e.g., 2E3) bind an epitope involving residue Asp90, avoiding interference with T-cell receptor (TCR) or CD8 binding sites .

Therapeutic Implications

• Desensitization: Plasmapheresis and IVIg reduce HLA-A antibody titers in 60–70% of cases .

• Functional Matching: Avoid donors with HLA-A alleles targeted by high-MFI (>8,000) antibodies .

Research Challenges

• Heterogeneity: Not all HLA-A antibodies are pathogenic; factors like IgG subclass and epitope specificity influence outcomes .

• Assay Limitations: Luminex® may detect non-functional antibodies, necessitating adjunct flow crossmatch testing .